

October 20, 2020

BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 <u>Scrip code: 532531</u> **The National Stock Exchange of India Limited** Exchange Plaza, Bandra-Kurla Complex Bandra (E) Mumbai - 400 051 <u>Scrip code: STAR</u>

Dear Madam/ Sir,

Sub: Press Release

Please find attached Press Release issued by the Company titled:

"Strides receives USFDA approval for Ethacrynic Acid Tablets"

Thanks & Regards, For **Strides Pharma Science Limited**,

Manjula R.

Manjula Ramamurthy Company Secretary

Encl. As above





Strides receives USFDA approval for Ethacrynic Acid Tablets

To be marketed by Strides Pharma Inc. in the US market

Bengaluru, October 20, 2020 – Strides Pharma Science Limited (Strides) today announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for *Ethacrynic Acid Tablets USP, 25 mg* from the United States Food & Drug Administration (USFDA). The product is a generic version of Edecrin[®] Tablets, 25 mg, of Bausch Health Americas, Inc.

According to IQVIA MAT August 2020 data, the US market for Ethacrynic Acid Tablets USP, 25 mg is approximately US\$ 14 Mn. The product will be manufactured at the company's flagship facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 126 cumulative ANDA filings with USFDA of which 92 ANDAs have been approved and 34 are pending approval.

About Ethacrynic Acid Tablets

Ethacrynic acid is in a class of medications called diuretics ('water pills'). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.

About Strides

Strides, listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bengaluru, India. The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy along with an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi) and the United States (Florida). The Company focusses on "difficult to manufacture" products that are sold in over 100 countries. Additional information is available at the Company's website at <u>www.strides.com</u>

For further information, please contact:

<u>Strides</u>	Corporate Communication
Badree Komandur	Usha lyer: +91 9987444106
Executive Director – Finance & Group CFO +91 80 6784 0747	Email: usha.iyer@strides.com
Investor Relations Sandeep Baid: +91 80 6784 0791 Email: <u>Sandeep.baid@strides.com</u>	PR Consultancy Fortuna PR K Srinivas Reddy: +91 90005 27213 srinivas@fortunapr.com
	K Priya: +91 95354 25418 priya@fortunapr.com

Strides Pharma Science Limited	
CIN: L24230MH1990PLC057062	
Regd. Office: 201, 'Devavrata', Sector - 17, Vashi, Navi Mumbai - 400 703	
Corp. Office: Strides House, Bannerghatta Road, Bengaluru – 560 076	